Brief: Processa Pharma Terminates Prospectus Supplement Related To Company's Common Stock, Par Value $0.0001 Per Share

Processa Pharmaceuticals

06/02/2023 16:49

Feb 6 (Reuters) - Processa Pharmaceuticals Inc  PCSA.O :
    * PROCESSA PHARMACEUTICALS INC -  ON FEB 6 CO TERMINATED
PROSPECTUS SUPPLEMENT RELATED TO COMPANY'S COMMON STOCK, PAR
VALUE $0.0001 PER SHARE
    * PROCESSA PHARMACEUTICALS INC -  ON FEB 5 CO DELIVERED
WRITTEN
NOTICE TO OPPENHEIMER & CO. INC OF SUCH TERMINATION
    * PROCESSA PHARMACEUTICALS INC -  CO INTENDS TO SUSPEND
FURTHER
ENROLLMENT IN PCS499 TRIAL FOR ULCERATIVE NECROBIOSIS LIPOIDICA
    * PROCESSA PHARMACEUTICALS INC -  CO HAS BEGUN, TO CONTINUE
TO
MEET POTENTIAL LICENSING PARTNERS, CONSIDER OTHER OPTIONS TO
MONETIZE PCS12852 AND PCS499
    * PROCESSA PHARMACEUTICALS- CO TO SUSPEND SALE OF ATM SHARES
PURSUANT TO EQUITY DISTRIBUTION AGREEMENT UNLESS AND UNTIL NEW
PROSPECTUS SUPPLEMENT FILED

Source text: (https://bit.ly/3Y5oGZK)
Further company coverage:  PCSA.O 
 ((Reuters.Briefs@thomsonreuters.com;))